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A B S T R A C T
We describe two cases of patients with emphysema who, in the lead up to hyperinﬂation intervention, developed
pneumonia with signiﬁcant physiological, anatomical, functional and quality of life improvement observed
following. This directly goes against the natural history of both disease processes, demonstrating the beneﬁt
resulting from infective autobullectomy.
1. Introduction
Hyperinﬂation results from collapsible, distended, over-compliant
portions of lung trapping air. Consequently, there is a failure to eﬀec-
tively expire, increasing residual volume (RV). This leads to patients
breathing at higher lung volumes, impinging on lung reserve. Reducing
hyperinﬂation and restoring lung reserve has the potential to func-
tionally and clinically improve patients’ health and outcomes. This is a
rapidly developing area for targeted interventions with surgery, valves
and coils occupying varying positions in clinical practice.
Multidisciplinary hyperinﬂation services are emerging, utilising phy-
siology, imaging, functional and collateral ventilation assessments to
evaluate patients. Naturally occurring improvements in the context of
autobullectomy are recognised [1–3].
2. Materials and methods
Two patients were seen at a specialist respiratory centre which
conﬁrmed and managed their COPD. Neither patient has co-existent
atopic conditions or known history of atopy. Both patients had full
before and after pneumonic episode spirometry, chest plain radiograph,
BODE scores, CAT scores and 6-min walking distances (6MWD) re-
corded. Case one shows signiﬁcant improvement on CT scans done pre-
and post-pneumonic episodes, which are not available for case two.
Case one also has a full St George's Respiratory Questionnaire for both
before and after. Both were treated with co-amoxiclav and cipro-
ﬂoxacin, guided by microbiology cultures and sensitivity screens.
3. Results
3.1. Case 1
A 64-year-old male presented with left upper lobe pneumonia, on a
background of severe emphysema. His concurrent asthma was well
controlled, as suggested by his< 25 ppb FeNO. He had completed
pulmonary rehabilitation but was unsuccessful in smoking cessation.
LVRS was being considered, having been excluded for EBVs due to the
presence of collateral ventilation. Over the previous seven years, his
lung function had progressively declined (FEV1 1.13l reduced to 0.97l).
His exertion was normally limited to 90m and he experienced recurrent
exacerbations and deterioration of breathlessness. CT showed severe
emphysema with pan-lobular upper lobe predominance.
Sixteen months following pneumonia, lung function showed im-
provement. Chest radiograph showed reduced hyperinﬂation (Fig. 1,
recovery; Fig. 2, case 1, recovery). He described feeling he could do
‘three times more than previously’ and is more conﬁdent about his
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heath, which is reﬂected in his CAT and 6MWD.
3.2. Case 2
A 40-year-old male presented with lung infection of his upper zones.
CT showed bullae measuring up to 15cm, replacing almost the entire
upper lobe, occupying approximately 50% of the lung volume.
Compressive atelectasis within the middle lobe and lingula and minimal
abnormalities in the lower lobes were also observed. He previously
smoked cigarettes (32 pack years) and cannabis daily throughout his
20s (resin and leaf). He demonstrates normal eosinophil and IgE levels
in blood tests. His ﬁtness at presentation meant he did not stop walking
throughout his 6MWD, placing him beyond the ceiling of the test. He
has completed a pulmonary rehabilitation course in the past.
After 3 episodes of infection in his bullous spaces over 3 years, each
requiring long term antibiotics, his lung function improved (Fig. 3,
Table 1). He reports feeling ‘brilliant’ and has taken up mountain
biking. On CT, a residual opacity, 10% of the size of the bulla replaced
the space of his left upper lobe bullae. Chest radiograph showed su-
perior retraction of his left hilum, tenting of the left hemidiaphragm
and reduction in the size of bullous spaces (Fig. 2, case 2, recovery).
Both patients continue to experience improved lung function, as
described above, with functional improvement, and continue to be seen
routinely for monitoring in clinic.
4. Discussion
Both of our patients had aspects of physiological or clinical im-
provement of signiﬁcance following pneumonic episodes. Signiﬁcantly,
improvements seen in FEV1 in both cases were beyond minimal clini-
cally important diﬀerences (MCIDs). Reported beneﬁts included an
increased walking distance in case one and case two returning to
mountain biking. These cases demonstrate that in the context of diﬀuse
emphysema, rather than discrete bullae, co-located infection can have
Fig. 1. Case 1 CT chest: pre- during- and post-pneumonia. There is consolidation superimposed on emphysematous changes in the left upper lobe during the acute
pneumonia. The CT post recovery demonstrates scarring in the left upper lobe, with volume loss, as evidenced by anterior displacement of the left oblique ﬁssure
compared to the baseline CT.
Fig. 2. Chest plain radiographs for both cases showing pre-, during- and post-pneumonia radiology.
Chest plain radiographs for both cases showing pre-, during- and post-pneumonia radiology.
Case 1: During-pneumonia plain radiograph demonstrates left upper lobe consolidation superimposed upon emphysema. Mild resulting volume loss on the post
pneumonia image, better demonstrated by CT imaging in Fig. 1.
Case 2: Multiple air ﬂuid levels within bilateral bulla in the upper zones, with a rounded opacity in the Left upper zone representing a large ﬂuid ﬁlled bulla during-
pneumonia imaging. Post pneumonia plain radiograph demonstrates volume loss in the left upper lobe as evidenced by superior retraction of the left hilar and tenting
of the left hemidiaphragm.
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distinct impact.
Lung function signiﬁcantly improved in both. There were more
varying impacts upon walking distance achieved. Interestingly, likely
due to volume correction, gas transfer was also impacted. All these
ﬁndings are directly against the natural history of the disease and initial
measurements were all taken in the stable optimally medically treated
state.
Case one demonstrated a large improvement in 6MWD and FEV1
following pneumonia, both signiﬁcantly above MCIDs. His global in-
itiative for chronic obstructive lung disease (GOLD) staging changed
from stage 4 (very severe) to stage 3 (severe), a marked improvement,
which is reﬂected in his health-related quality of life assessment (CAT
score).
Case two normalised his lung function values (FEV1, FEV/FVC, RV),
despite imaging showing the presence of bullous disease. The reduction
in atelectasis of his middle and lower lobe is reﬂected in his increased
VA. This, rather than a reduction in alveolar exchange eﬃcacy, explains
the decrease in KCO. As he no longer smokes cigarettes or cannabis, we
anticipate his lung function will remain stable and do not expect to
observe decline in the future.
Emphysema is characterised by the abnormal permanent enlarge-
ment of the air spaces distal to the terminal bronchioles, accompanied
by destruction of alveolar walls. This occurs following a sequence of
inﬂammatory processes, obstruction from mucus hypersecretion and
subsequent entrapment and alveolar distension or destruction. The
surrounding bronchioles are compressed, increasing airway resistance
and the eﬀort required to maintain breathing eﬀorts.
The functional sum of this is dynamic hyperinﬂation; a premature
inspiratory breath before end expiration. This adds to the trapping of air
in the hyperinﬂated lung. Exertion normally raises the respiratory rate
by shortening expiratory phase. Obstruction in emphysema (which is
most pronounced on expiration) combined with the shortened ex-
piratory phase causes incomplete expiration on exertion, increasing air
trapping and hyperinﬂation.
Hyperinﬂation therefore has devastating clinical impacts. Newer
interventions, targeting the most diseased parts of lung, have a growing
evidence base and are discussed for comparison to observed post-
pneumonic improvements. However, medical therapy is the mainstay of
COPD management in clinic. In comparison to control, the TORCH trial
demonstrated signiﬁcant improvements in FEV1 with salmeterol and
ﬂuticasone respectively and further improvement with combination
therapy [5]. The UPLIFT trial demonstrated the beneﬁt of tiotropium
over placebo at regular time points in 5993 patients over four years in
pre-bronchodilator FEV1 and SGRQ scores [6]. These studies and others
have formed the basis of our long-term pharmacological management
of COPD.
While medical therapy has impacted upon symptoms, additional
core elements of eﬀective support to people with COPD are pulmonary
rehabilitation, smoking cessation and vaccination. Pulmonary re-
habilitation signiﬁcantly impacts upon symptoms, quality of life, ex-
ercise capacity as well as exacerbation frequency [7].
4.1. Mechanism of improvement
There are no data outside the context of case reports that describe
the processes of the mechanistic reductions of hyperinﬂation in pneu-
monia. However, the pathophysiology of lung parenchymal changes in
infection is well characterised.
As bacterial infections occur in emphysematous portions of lung;
ﬁbrous, non-compliant scar tissue replaces the lung tissue. This occurs
after substantial tissue destruction via the inﬂammatory process.
Connective tissue grows into the area of damage or exudate, converting
it into a mass of ﬁbrous tissue. Additionally, the Th2 immune response
to bacteria is hypothesised to be a potent driver of ﬁbrosis [8].
Bacterial toxins and inﬂammatory processes cause the destruction of
large amounts of delicate, normal, compliant lung tissue. Inﬂammation
involves the release of various cytokines, including those essential to
organising resolution (TNF, PDGF, FGF-2 and TGF-β). TGF- β, EGF,
PDGF and FGF, produced by inﬂammatory cells, promote ﬁbroblast
proliferation, while their migration is supported by the cytokines IL-1
and TNF. Fibroblast activity leads to collagen ﬁbril and ﬁbronectin
deposition, in the lung parenchyma. Simultaneously, the inhibition of
matrix metalloproteases by cytokines decreases extracellular matrix
breakdown, leading to signiﬁcant amounts of ﬁbrous collagen dense
connective tissue being laid down. As the inﬂammatory process ter-
minates, healing progresses and the number of proliferating ﬁbroblasts
decrease. However, the ﬁbroblasts assume a more synthetic phenotype,
depositing extracellular matrix, maintaining this state over a period of
weeks. As collagen continues to be synthesised, the tissue becomes
more ﬁbrotic in nature. Furthermore, some ﬁbroblasts transform into
myoﬁbroblasts, acquiring features of smooth muscle, including actin
ﬁlaments, causing contraction of tissue [8,9].
Thus, as bacterial infections occur in emphysematous portions of
lung; ﬁbrous, non-compliant scar tissue replaces the lung tissue. It is
likely that, if co-located in the most emphysematous portions of lung,
the compliance of these portions of lung would improve. If allowed to
Fig. 3. Case 2's Flow-Volume loops, demonstrating improvement post pneumonic episodes.
K. Kayani et al. Respiratory Medicine Case Reports 26 (2019) 1–5
3
continue further, it may even lead to shrinkage of these portions of lung
as over-compliant tissue is replaced with uncompliant, contracted ﬁ-
brous tissue. This ﬁbrous tissue is less collapsible and not liable to air
trapping and hyperinﬂation. This process is analogous to some of the
surgical or endoscopic means by which attempts are made to reduce
hyperinﬂation (discussed below).
As the most diseased portions of lung contract and recede, less
diseased portions expand. Air enters portions of the lung with healthier
alveoli, improving gas exchange. Reducing hyperinﬂation also im-
proves lung mechanics and lung elasticity, further enhanced by the
presence of new ﬁbrous tissue.
4.2. Surgical lung volume reduction (LVRS)
LVRS removes the most diseased portions of lung, reducing hyper-
inﬂation and improving lung mechanics. Reduction in distention im-
proves elastic lung elasticity, the position of the diaphragm and ability
of intercostal muscles to increase inspiratory pressures. The NETT trial
studied 1218 patients and found LVRS improves long term survival,
measured at one year. However, it failed to reach its primary endpoint
of mortality reduction. Instead, it was associated with a high 90-day
mortality rate (7.9% vs 1.3% medically managed). Nevertheless, post
hoc analysis showed, in those with predominantly upper lobe disease
and low exercise tolerance, LVRS gave a signiﬁcant survival advantage
as opposed to usual medical management [10].
Emphasising the importance of patient selection in achieving good
outcomes, a 2016 Cochrane library review of LVRS found FEV1 in LVRS
treated patients to be 0.2 l higher than control groups [11]. Similarly,
6MWDs were 0.7 standard deviations higher in the LVRS group, while
SGRQ scores were 13.78 points lower. NICE have since approved LVRS
in select patients and despite early mortality concerns, some centres are
now reporting a less than 1% 90-day mortality rate [12,13].
4.3. Endobronchial valves (EBVs)
The early mortality concerns and complexity associated with LVRS
has made EBVs attractive. EBVs allow air out of a diseased lung lobe,
but not in, progressively causing atelectasis, reducing hyperinﬂation,
with similar eﬀects to LVRS. The BeLieVer-HIFi study enrolled 50 pa-
tients with intact interlobular ﬁssures and heterogeneous emphysema.
Mean FEV1 improved by 24.8% in the EBV group (n=25) compared
with 3.9% in the sham group. However, two patients died in the in-
tervention group and there was signiﬁcant spread in the results of the
intervention group. Post hoc analysis demonstrated improved responses
in FEV1, 6MWD and exercise endurance in patients with no collateral
ventilation on chartis assessment, which was later conﬁrmed by the
IMPACT study [14,15].
However, those considered for valves should be assessed for their
ability to survive pneumothorax, the most common complication of
valve insertion [16,17]. These, however, can usually be conservatively
managed without incident. EBVs are currently approved by NICE for
use as a means of lung volume reduction [18].
4.4. Endobronchial coils (EBCs)
EBCs are currently in Phase III trials and are a potential alternative
to EBVs. The RESET trial compared 24 standard care patients with 23
coil treated patients. Directly comparing the two groups, the coil group
improved in FEV1 (10.6%), RV (−0.31l), 6MWD (63.6m) and SGRQ
(−8.36 points). This study demonstrated the safety of EBCs and their
success in targeting homogenous emphysema, a disease form which has
been unamenable to LVRS and EBVs [19].
The RENEW trial enrolled 315 patients, comparing EBCs and usual
care to usual care alone. At one year, 40% of coil patients had a greater
than 25m change in 6MWD (vs 26.9% of controls) and between group
median diﬀerences were signiﬁcantly in favour of EBC patients (FEV1:
7.0%, SGRQ: 8.9 points). Importantly, there was no excess in death.
However, more instances of pneumonia (20% coils vs 4.5%) and
pneumothorax (9.7% vs 0.6%) were observed. Post-hoc analysis from
this study however shows that one third of the pneumonias identiﬁed
were coil opacities [20]. While studies have shown promising data for
EBCs in select patients, they are currently recommended by NICE only
in the context of research [21].
5. Conclusions
Clinically meaningful beneﬁts resulted following the occurrences of
pneumonia in the most diseased portions of lung in varying clinical
Table 1
Table showing lung function testing and parameters for both patients at time
points before and after pneumonia. Note, case 2 completed a 6MWD with no
breaks, achieving a distance of 490. Thus, no further 6MWD was completed
owing to his improved lung function since his last test.
Pre-Pneumonia Post-
Pneumonia
Absolute
change
(Post-Pre)
% change
from
baseline
CASE 1
FEV1 (L) (% pred) 0.97 (27) 1.18 (33.7) 0.21 (6.7) 21.65
(24.81)
FVC (L) 3.83 3.27 −0.56 −14.62
VC max (L) 4.23 4.79 0.56 13.24
FEV % VC max 22.93 30.94 8.01 34.93
TLC (L) 10.89 10.69 −0.2 −1.84
RV (L) 6.82 5.89 −0.93 −13.64
RV/TLC (%) 62.65 55.13 −7.52 −12.00
VC (L) 4.07 4.79 0.72 17.69
TLCO [mmol/
(min*kPa)]
3.37 4.78 1.41 41.84
KCO [mmol/
(min*kPa*L)]
0.54 0.54 0 0.00
VA (L) 6.27 8.78 2.51 40.03
6MWD (m) 120 220 100 83.33
BODE 9 8 −1 −11.11
MMRC dyspnoea
scale score
4 4 0 0.00
CAT score 32 29 −3 −9.38
SGRQ
health good poor
symptoms 97.05 89.05 −8 8.92
activity 100 100 0 0.00
impact 84.86 89.41 4.55 5.36
total 91.66 92.6 0.94 1.03
BMI 26.73 22 −4.73 −17.70
CASE 2
FEV1 (L) (% pred) 2.38 (56.6) 4.51 (111) 2.13 (54.4) 89.50
(96.11)
FVC (L) 4.9 6.2 1.3 26.53
VC max (L) 4.9 6.3 1.4 28.57
FEV % VC max 48.59 71.62 23.03 47.40
TLC (L) 8.31 7.77 −0.54 −6.50
RV (L) 3.68 1.76 −1.92 −52.17
RV/TLC (%) 44.23 22.59 −21.64 −48.93
VC (L) 4.64 6.01 1.37 29.53
TLCO [mmol/
(min*kPa)]
10.11 10.65 0.54 5.34
KCO [mmol/
(min*kPa*L)]
1.82 1.54 −0.28 −15.38
VA 5.56 6.93 1.37 24.64
Jones et al (2014) deﬁned minimal clinically important diﬀerences (MCIDs) in
COPD as: FEV1 change of 100 ml, health status change by 4 units in the St
George's Respiratory Questionnaire (SGRQ) (health improvement giving a re-
duction in score) and change in exercise capacity as 26± 2m in 6 minute
walking distance [4].
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phenotypes of emphysema.
6. Limitations
We recognise this is an isolated cases series and did not involve
prospective identiﬁcation of patients with emphysema and pneumonia.
Furthermore, clearly pneumonia poses a signiﬁcant risk to people with
advanced lung disease and we do not know the prevalence of this po-
sitive phenomenon. Nevertheless, we have shown unexpected sig-
niﬁcant improvement within their own right in these cases. We re-
cognise that quantiﬁed CT would be the gold standard for identifying
change to hyperinﬂation, however chest radiographs are routinely
performed following pneumonia and can provide indications of re-
ductions in hyperinﬂation.
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